tetano
Editor, Senior Moderator
PLoS One
. 2024 Mar 1;19(3):e0290913.
doi: 10.1371/journal.pone.0290913. eCollection 2024. Seroepidemiology of SARS-CoV-2 in a cohort of pregnant women and their infants in Uganda and Malawi
Lauren Hookham[SUP] 1 [/SUP], Liberty Cantrell[SUP] 2 [/SUP], Stephen Cose[SUP] 3 4 [/SUP], Bridget Freyne[SUP] 5 6 7 [/SUP], Luis Gadama[SUP] 8 [/SUP], Esther Imede[SUP] 4 [/SUP], Kondwani Kawaza[SUP] 8 [/SUP], Samantha Lissauer[SUP] 5 6 [/SUP], Phillipa Musoke[SUP] 9 [/SUP], Victoria Nankabirwa[SUP] 10 [/SUP], Musa Sekikubo[SUP] 11 [/SUP], Halvor Sommerfelt[SUP] 12 13 [/SUP], Merryn Voysey[SUP] 2 [/SUP], Kirsty Le Doare[SUP] 1 14 [/SUP]; periCOVID Consortium
Affiliations
Background: Data on SARS-CoV-2 infection in pregnancy and infancy has accumulated throughout the course of the pandemic, though evidence regarding asymptomatic SARS-CoV-2 infection and adverse birth outcomes are scarce. Limited information is available from countries in sub-Saharan Africa (SSA). The pregnant woman and infant COVID in Africa study (PeriCOVID Africa) is a South-South-North partnership involving hospitals and health centres in five countries: Malawi, Uganda, Mozambique, The Gambia, and Kenya. The study leveraged data from three ongoing prospective cohort studies: Preparing for Group B Streptococcal Vaccines (GBS PREPARE), SARS-CoV-2 infection and COVID-19 in women and their infants in Kampala and Mukono (COMAC) and Pregnancy Care Integrating Translational Science Everywhere (PRECISE). In this paper we describe the seroepidemiology of SARS-CoV-2 infection in pregnant women enrolled in sites in Uganda and Malawi, and the impact of SARS-CoV-2 infection on pregnancy and infant outcomes.
Outcome: Seroprevalence of SARS-CoV-2 antibodies in maternal blood, reported as the proportion of seropositive women by study site and wave of COVID-19 within each country.
Methods: The PeriCOVID study was a prospective mother-infant cohort study that recruited pregnant women at any gestation antenatally or on the day of delivery. Maternal and cord blood samples were tested for SARS-CoV-2 antibodies using Wantai and Euroimmune ELISA. In periCOVID Uganda and Malawi nose and throat swabs for SARS-Cov-2 RT-PCR were obtained.
Results: In total, 1379 women were enrolled, giving birth to 1387 infants. Overall, 63% of pregnant women had a SARS-CoV-2 positive serology. Over subsequent waves (delta and omicron), in the absence of vaccination, seropositivity rose from 20% to over 80%. The placental transfer GMR was 1.7, indicating active placental transfer of anti-spike IgG. There was no association between SARS-CoV-2 antibody positivity and adverse pregnancy or infancy outcomes.
. 2024 Mar 1;19(3):e0290913.
doi: 10.1371/journal.pone.0290913. eCollection 2024. Seroepidemiology of SARS-CoV-2 in a cohort of pregnant women and their infants in Uganda and Malawi
Lauren Hookham[SUP] 1 [/SUP], Liberty Cantrell[SUP] 2 [/SUP], Stephen Cose[SUP] 3 4 [/SUP], Bridget Freyne[SUP] 5 6 7 [/SUP], Luis Gadama[SUP] 8 [/SUP], Esther Imede[SUP] 4 [/SUP], Kondwani Kawaza[SUP] 8 [/SUP], Samantha Lissauer[SUP] 5 6 [/SUP], Phillipa Musoke[SUP] 9 [/SUP], Victoria Nankabirwa[SUP] 10 [/SUP], Musa Sekikubo[SUP] 11 [/SUP], Halvor Sommerfelt[SUP] 12 13 [/SUP], Merryn Voysey[SUP] 2 [/SUP], Kirsty Le Doare[SUP] 1 14 [/SUP]; periCOVID Consortium
Affiliations
- PMID: 38427691
- PMCID: PMC10906847
- DOI: 10.1371/journal.pone.0290913
Background: Data on SARS-CoV-2 infection in pregnancy and infancy has accumulated throughout the course of the pandemic, though evidence regarding asymptomatic SARS-CoV-2 infection and adverse birth outcomes are scarce. Limited information is available from countries in sub-Saharan Africa (SSA). The pregnant woman and infant COVID in Africa study (PeriCOVID Africa) is a South-South-North partnership involving hospitals and health centres in five countries: Malawi, Uganda, Mozambique, The Gambia, and Kenya. The study leveraged data from three ongoing prospective cohort studies: Preparing for Group B Streptococcal Vaccines (GBS PREPARE), SARS-CoV-2 infection and COVID-19 in women and their infants in Kampala and Mukono (COMAC) and Pregnancy Care Integrating Translational Science Everywhere (PRECISE). In this paper we describe the seroepidemiology of SARS-CoV-2 infection in pregnant women enrolled in sites in Uganda and Malawi, and the impact of SARS-CoV-2 infection on pregnancy and infant outcomes.
Outcome: Seroprevalence of SARS-CoV-2 antibodies in maternal blood, reported as the proportion of seropositive women by study site and wave of COVID-19 within each country.
Methods: The PeriCOVID study was a prospective mother-infant cohort study that recruited pregnant women at any gestation antenatally or on the day of delivery. Maternal and cord blood samples were tested for SARS-CoV-2 antibodies using Wantai and Euroimmune ELISA. In periCOVID Uganda and Malawi nose and throat swabs for SARS-Cov-2 RT-PCR were obtained.
Results: In total, 1379 women were enrolled, giving birth to 1387 infants. Overall, 63% of pregnant women had a SARS-CoV-2 positive serology. Over subsequent waves (delta and omicron), in the absence of vaccination, seropositivity rose from 20% to over 80%. The placental transfer GMR was 1.7, indicating active placental transfer of anti-spike IgG. There was no association between SARS-CoV-2 antibody positivity and adverse pregnancy or infancy outcomes.